Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/12702
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Greenhalgh, J | - |
dc.contributor.author | Longworth, L | - |
dc.contributor.author | Crossan, C | - |
dc.contributor.author | Singh, J | - |
dc.contributor.author | Bagust, A | - |
dc.contributor.author | Beale, S | - |
dc.contributor.author | Richardson, M | - |
dc.contributor.author | Banks, L | - |
dc.contributor.author | Kotas, E | - |
dc.contributor.author | Hall, M | - |
dc.date.accessioned | 2016-06-02T10:02:37Z | - |
dc.date.available | 2015-09-23 | - |
dc.date.available | 2016-06-02T10:02:37Z | - |
dc.date.copyright | 2015-09-23 | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Greenhalgh, J., Longworth, L., Crossan, C., Singh, J., Bagust, A., Beale, S., Richardson, M., Banks, L., Kotas, E. and Hall, M. (September 2015) 'Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE', NICE technology appraisal guidance (TA355), pp. 1 - 40. ISBN: 978-1-4731-1440-1. | en_US |
dc.identifier.isbn | 978-1-4731-1440-1 | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/12702 | - |
dc.description.abstract | 1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including: congestive heart failure hypertension diabetes prior stroke or transient ischaemic attack age 75 years or older. | en_US |
dc.description.uri | https://www.nice.org.uk/guidance/ta355 | - |
dc.language.iso | en | en_US |
dc.publisher | National Institute for Health and Care Excellence (NICE) | en_US |
dc.rights | NICE UK Open Content Licence This licence allows individuals, commercial organisations and non-commercial organisations to reuse NICE content free of charge in their publications, products and systems. It applies to requests to use our content in a UK setting only. Note - If you plan to use our content in an international setting, you must submit the International use of NICE content form. Using our content in the UK The NICE UK Open Content Licence is a self-assessment exercise: Read the licence [see URL] below carefully before using our content and adhere to its terms and conditions. Please fill in the 'Use of NICE content' form below telling us how you intend to use our content: https://www.nice.org.uk/re-using-our-content/uk-open-content-licence | - |
dc.rights.uri | https://www.nice.org.uk/re-using-our-content/uk-open-content-licence | - |
dc.subject | Guidance | en_US |
dc.subject | Edoxaban | en_US |
dc.subject | Stroke | en_US |
dc.subject | Prevention | en_US |
dc.subject | Systemic embolism | en_US |
dc.title | Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE | en_US |
dc.type | Other | en_US |
pubs.commissioning-body | NICE | - |
pubs.commissioning-body | NICE | - |
pubs.confidential | false | - |
pubs.confidential | false | - |
pubs.place-of-publication | London, UK | - |
Appears in Collections: | Health Economics Research Group (HERG) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 232.75 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.